---
title: "Elicio Therapeutics, Inc. (ELTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ELTX.US.md"
symbol: "ELTX.US"
name: "Elicio Therapeutics, Inc."
industry: "生物技術"
---

# Elicio Therapeutics, Inc. (ELTX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [elicio.com](https://elicio.com) |

## Company Profile

Elicio Therapeutics, Inc.是一家臨床階段的生物技術公司，開發用于癌症治療的免疫療法。其主要產品候選藥物是 ELI-002，一種多價淋巴結靶向的兩親性（AMP）肽疫苗，目前正在進行針對七種 Kirsten 大鼠肉瘤病毒癌基因同源物驅動突變的二期臨床試驗。該公司還開發了 ELI-007，一種多價淋巴結靶向的 AMP 肽疫苗，目前處于針對突變 b-raf 小鼠肉瘤病毒癌基因同源物 B1 驅動癌症的臨床前研究階段；以及 ELI-008，一種多價淋巴結靶向的 AMP 肽疫苗，目前也處于針對突變腫瘤蛋白 p53 表達癌症的臨床前研究階段。Elicio Therapeutics, I...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.26 | 322/605 | - | - | - |
| PB | 39.15 | 428/605 | 92.21 | 37.48 | 14.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-27T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.55 |
| Highest Target | 18.00 |
| Lowest Target | 13.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ELTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ELTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ELTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.